Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beta Bionics, Inc.BBNX · Entity 2350 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beta Bionics, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,397 |
Ending reported balance
After 2026-05-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-21 · Sale · Disposed 1,000 · Balance 11,432 F1: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025. Row 2 · 2026-05-21 · Grant · Acquired 16,965 · Balance 28,397 F2: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. |
| Comon StockSEC Table I · non-derivative | Direct | 27,399 |
Reported balance
After 2026-05-22 transaction · row 3
1 source rowRow 3 · 2026-05-22 · Sale · Disposed 998 · Balance 27,399 F1: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025.
F2: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 22, 2026 Filed May 26, 2026 22:00 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleComon Stock | 998 | $11.21 | $11,187.58 |
DisclosureSEC source: 0002048466-26-000003 · form4-05262026_060522.xml · nonDerivative · entry 3 Lezack Adam · CIK 0002048466 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,399 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025. Read SEC document |
| May 21, 2026 Filed May 26, 2026 22:00 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantCommon Stock | 16,965 | $0.00 | $0.00 |
DisclosureSEC source: 0002048466-26-000003 · form4-05262026_060522.xml · nonDerivative · entry 2 Lezack Adam · CIK 0002048466 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,397 F2 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| May 21, 2026 Filed May 26, 2026 22:00 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 1,000 | $9.95 | $9,950.00 |
DisclosureSEC source: 0002048466-26-000003 · form4-05262026_060522.xml · nonDerivative · entry 1 Lezack Adam · CIK 0002048466 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,432 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantCommon Stock | 3,997 | $0.00 | $0.00 |
DisclosureSEC source: 0002048466-26-000002 · form4-01142026_080103.xml · nonDerivative · entry 1 Lezack Adam · CIK 0002048466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,432 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:20 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 500 | $29.91 | $14,955.00 |
DisclosureSEC source: 0002048466-25-000005 · form4-12022025_041204.xml · nonDerivative · entry 2 Lezack Adam · CIK 0002048466 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,435 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025. F3 · price: The weighted average sale price for the transaction reported was $29.91 and the range of prices were between $29.80 and $30.16. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:20 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 906 | $29.35 | $26,587.75 |
DisclosureSEC source: 0002048466-25-000005 · form4-12022025_041204.xml · nonDerivative · entry 1 Lezack Adam · CIK 0002048466 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,935 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025. F2 · price: The weighted average sale price for the transaction reported was $29.3463 and the range of prices were between $28.75 and $29.63. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 31, 2025 Filed Nov 6, 2025 02:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 38 | $27.70 | $1,052.60 |
DisclosureSEC source: 0002048466-25-000003 · form4-11052025_091104.xml · nonDerivative · entry 2 Lezack Adam · CIK 0002048466 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,841 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025. Read SEC document |
| October 31, 2025 Filed Nov 6, 2025 02:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 1,368 | $26.85 | $36,727.24 |
DisclosureSEC source: 0002048466-25-000003 · form4-11052025_091104.xml · nonDerivative · entry 1 Lezack Adam · CIK 0002048466 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,879 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025. F2 · price: The weighted average sale price for the transaction reported was $26.8474 and the range of prices were between $26.27 and $27.24. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 15, 2025 Filed Mar 19, 2025 00:00 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantCommon Stock | 11,247 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008534 · form4-03182025_080304.xml · nonDerivative · entry 1 Lezack Adam · CIK 0002048466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,247 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantDirector Stock Option (right to buy) · Derivative | 9,137 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001415889-25-002820 · form4-02032025_080213.xml · derivative · entry 1 Lezack Adam · CIK 0002048466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,137 Underlying: Common Stock · 9,137 shares Expires 2033-12-11 F1 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments measured from December 12, 2023. F2 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.